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What’s already known about this topic? 
 Prenatal Down syndrome screening markers in unaffected twin pregnancies are 
approximately double those in singleton pregnancies  
 It has generally been assumed that the proportional differences in serum marker levels in 
affected and unaffected singleton pregnancies can be applied to levels found in twin 
pregnancies 
 
What does this study add? 
 The median late first trimester free β-hCG level in monochorionic affected twin pregnancies 
is lower than levels based on the proportionality assumption, and the median PAPP-A level 
in dichorionic affected twin pregnancies is higher. 
  Combined test screening performance in monochorionic twins is similar to that in 
singletons, but lower in dichorionic twins 
 Different Combined test risk cut-offs in monochorionic and dichorionic twin pregnancies 
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ABSTRACT 
Objective: To determine whether assumptions used in prenatal screening for Down syndrome in 
twin pregnancies are valid, and derive estimates of risk and screening performance in twin 
pregnancies using observed data. 
Methods: Data were collected on nuchal translucency, chorionicity, pregnancy associated plasma 
protein-A (PAPP-A) and free ß human chorionic gonadotrophin (free ß-hCG) from 61 twin 
pregnancies with Down syndrome and 7,302 unaffected twin pregnancies. Distribution parameters 
were determined, and used to estimate screening performance. 
Results: The assumption that proportional differences in serum marker levels in affected and 
unaffected singleton pregnancies apply to twin pregnancies was not confirmed. Median free β-hCG 
value in monochorionic affected twin pregnancies (2.63 multiples of the median (MoM), 95% CI 
1.79-3.22MoM)) was lower than that assuming proportionality (3.76 MoM), but the median PAPP-A 
value in dichorionic affected twin pregnancies (1.88 MoM (95% CI 1.60-2.17 MoM)) was higher than 
based on proportionality (1.33 MoM). The detection rate was 87% for a 3% false-positive rate in 
monochorionic twin pregnancies, and 74% in dichorionic twin pregnancies compared with 86% in 
singleton pregnancies. 
Conclusions: Estimates of screening performance in Down syndrome twin pregnancies do not need 
to rely on assumption and can take account of chorionicity and gestational age. 
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Introduction 
Prenatal screening for Down syndrome is more complex in twin pregnancies than in singleton 
pregnancies. Because of a lack of data on twin pregnancies with Down syndrome, estimates of the 
risk of having an affected twin pregnancy have relied on the assumption that the proportional 
differences in serum marker levels in affected and unaffected singleton pregnancies can be applied 
to levels found in twin pregnancies, which tend to be about twice as high.[1]  On this basis the 
median marker level in affected monochorionic twin pregnancies is taken as the median level in 
affected singleton pregnancies multiplied by the median level in unaffected twin pregnancies. 
Similarly the median marker level in dichorionic twins is taken as the average of the medians in 
unaffected and affected singleton pregnancies, multiplied by the median in unaffected twin 
pregnancies.[1] With marker levels expressed as multiple of the median (MoM) in unaffected 
singleton pregnancies (MoM), and based on these assumptions, the median late first trimester 
pregnancy associated plasma protein-A (PAPP-A) and  free β-human chorionic gonadotrophin (hCG) 
levels have been estimated to be 0.80 and 3.76 MoM respectively in monochorionic affected twin 
pregnancies and 1.33 and 2.93 MoM in dichorionic affected twin pregnancies respectively. [1]  The 
assumptions on which these estimates are based have not been empirically tested. We here do so 
using data from five screening centres. 
 
Methods 
Twenty-four twin pregnancies affected with Down syndrome were identified from the Wolfson 
Institute Screening Service, together with 7,302 unaffected twin pregnancies between January 2007 
and November 2016. An additional 37 affected twin pregnancies were identified from screening 
centres in Barcelona (12), Cambridge (5), Birmingham (15), and Sheffield.(5) Among the 61 affected 
twin pregnancies, 12 were monochorionic and 49 were dichorionic, and among the unaffected twin 
pregnancies 1,490 were monochorionic and 5,812 dichorionic. Marker levels for PAPP-A and free β-
hCG, together with measurements of the ultrasound marker nuchal translucency (NT) (ie the 
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Combined test markers) were reported to the study centre by each centre as multiples of the 
median (MoM) values so that the data could be combined without introducing bias. 
 
Median MoM values were calculated in monochorionic and dichorionic affected and unaffected twin 
pregnancies. For monochorionic twin pregnancies the geometric mean NT MoM value of the two 
separate fetus MoM values was used. Differences in median MoM values between monochorionic 
and dichorionic twin pregnancies were compared using the Wilcoxon rank sum test. Median 
regression was used to determine whether MoM values were influenced by gestational age. MoM 
values in twin pregnancies were calculated based on median values in unaffected twin pregnancies 
by dividing the reported MoM values by the median MoM in unaffected twin pregnancies given 
gestation and chorionicity and designated MOMT to indicate that the reference population is 
unaffected twin pregnancies, not singleton pregnancies. 
 
Medians, standard deviation and correlation coefficients were estimated for the markers in affected 
and unaffected twin pregnancies, together with truncations limits, to define the multivariate 
Gaussian distributions in affected and unaffected twin pregnancies. In unaffected twin pregnancies, 
for the two serum markers, standard deviations were estimated from a regression of values on 
probability plots between the 10th and 90th centile to avoid the influence of outliers. In affected twin 
pregnancies a regression of all values was used. For NT, standard deviations were estimated using all 
data to reflect the positive skew. [2] In unaffected pregnancies, correlation coefficients were 
estimated after excluding outlying values greater than 3.5 standard deviations from the mean for 
affected pregnancies, because of the small numbers, this was done by inspection of scatterplots 
(one excluded). Truncation limits were set on where the MoM values deviated from a Gaussian 
distribution i.e. deviated from the straight line on the probability plots in affected and unaffected 
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Screening performance was estimated using Monte Carlo simulation and multivariate Gaussian 
analyses. 100,000 affected and 100,000 unaffected pregnancies were simulated each separately for 
monochorionic and dichorionic pregnancies. This was done for the Combined test marker values 
(including a single NT MoM value for monochorionic twin pregnancies, and two NT MoM values for 
dichorionic twin pregnancies, taking into account any correlations between the two). Each 
pregnancy was assigned a maternal age based on the 2014-2016 maternal age distribution of 
England and Wales.[4] For each simulated monochorionic twin pregnancy, the risk of being affected 
with Down syndrome at term was calculated by multiplying the maternal age specific odds of having 
an affected singleton live birth [5], adjusted by the 66% reduction in risk of a  pregnancy being 
affected if it is a monochorionic twin pregnancy compared with a singleton pregnancy [6], by the 
likelihood ratio for being affected (for the simulated set of marker values) calculated from the 
multivariate Gaussian distributions of marker levels in affected and unaffected pregnancies. For each 
simulated dichorionic twin pregnancy, the risk of being affected with Down syndrome at term was 
calculated by multiplying half the maternal age specific odds of having an affected singleton live 
birth [5], adjusted by the 34% increase in risk of at least one of the fetuses being affected in a 
dichorionic twin pregnancy compared with a singleton pregnancy [6], by the likelihood ratio for each 
NT MoM value, summing the two and then multiplying that by the likelihood ratio for the serum 
markers. Risks were also calculated based on using NT alone, with maternal age. Screening 
performance was estimated as detection rates (DRs) for specified false-positive rates (FPRs), FPRs for 
specified DRs and DRs and FPRs for specified risk cut-offs. Screening performance in twin 
pregnancies was compared with that in singleton pregnancies using updated parameters from the 
Serum, Urine and Ultrasound Screening Study (SURUSS) [7][8] with a revised standard deviation for 
NT in unaffected pregnancies to take account of improvements in measuring NT over time, leading 
to decreases in the standard deviation of the log NT MoM values. The revised NT standard deviation 
was based on data from an audit of reflex DNA screening for Down syndrome, trisomy 18 and 
trisomy 13 [9]; among 22,706 unaffected pregnancies the log10 standard deviation was 0.0963 in 
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pregnancies screened in the 11th week of pregnancy and 0.0843 between 12 and 13 weeks, lower 
than the values we previously reported (0.1275 and 0.1105 respectively).[2] The lower standard 
deviation of 0.0843 was used in estimating screening performance in singleton pregnancies. 
Results 
Table 1 shows median NT, free β-hCG and PAPP-A MoM values for all twin pregnancies and 
according to chorionicity in Down syndrome and unaffected pregnancies. The table shows 
anticipated results, for example that the median NT MoM values for affected twin pregnancies are 
approximately double those in unaffected pregnancies (1.95 MoM) and two unexpected results, 
both relating to the two serum markers. First, the median free β -hCG value in monochorionic 
affected twin pregnancies was lower than that based on the proportionality assumption (3.76 MoM 
[1]), with an estimate of 2.63 MoM (95% confidence interval [CI] 1.79-3.22 MoM), an observation 
not observed in dichorionic affected twin pregnancies; the median (2.60 MoM, 95% CI 2.23-3.30 
MoM) was consistent with that based on the proportionality assumption (2.93 MoM [1). Second, the 
median PAPP-A value in dichorionic affected twin pregnancies was higher (1.88 MoM, 95% CI 1.60-
1.27 MoM) than that based on the proportionality assumption (1.33 MoM [1), an observation not 
made in monochorionic affected twin pregnancies; the median (0.83 MoM) was similar to that based 
on the proportionality assumption (0.80 MoM).[1] 
 
Figure 1 shows free β-hCG and PAPP-A MoM values in unaffected pregnancies according to 
gestational age, separately for monochorionic and dichorionic twin pregnancies. In monochorionic 
unaffected twin pregnancies there was no statistically significant change in free β -hCG MoM values, 
but in dichorionic unaffected twin pregnancies free β -hCG MoM values increased by 4.2% per week 
of gestation (95% CI 0.9% to 7.6%, p=0.003). In both monochorionic and dichorionic unaffected twin 
pregnancies there was a statistically significant increase in PAPP-A MoM values of 14.6% (95% CI 
8.7% to 20.9%, p<0.001) and 2.8% (95% CI 0.1% to 5.5%, p=0.039) respectively. Table 2 shows the 
parameters used to estimate risks and screening performance. 
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Figure 2 shows free β-hCG and PAPP-A expressed in MoM values for unaffected twin pregnancies in 
affected pregnancies according to gestational age, separately for monochorionic and dichorionic 
twin pregnancies. There was no indication of an effect of gestation on either marker in either 
monochorionic or dichorionic affected twin pregnancies but the statistical power to show an effect is 
limited. 
 
Figure 3 shows the detection rates for a 3% false-positive rate using NT alone with maternal age and 
the Combined test (which includes maternal age) in singleton pregnancies, monochorionic twin 
pregnancies and in dichorionic twin pregnancies. In singleton pregnancies the addition of the serum 
markers increased the detection rate by 10 percentage points (from 76% to 86%), by 13 percentage 
points in monochorionic twin pregnancies (from 74% to 87%) and by 4 percentage points in 
dichorionic twin pregnancies (from 70% to 74%). Table 3 shows estimates of screening performance 
for five specified false-positive rates and five specified detection rates. For example, the detection 
rate at a 3% false-positive rate was, respectively, 87% and 74% for monochorionic and dichorionic 
twin pregnancies. Table 4 shows detection rates and false-positive rates for a range of term risk cut-
offs. For example at a 1 in 150 risk cut-off the screening performance is 77% for a 0.6% false-positive 
rate in monochorionic twin pregnancies and 81% for a 6.4% false-positive rate in dichorionic twin 
pregnancies. The detection rates and the false-positive rates at a given risk cut-off are higher in 
dichorionic twin pregnancies than in monochorionic twin pregnancies. 
 
Table 5 shows the (rounded) risk cut-offs in singleton pregnancies, monochorionic, and dichorionic 
twin pregnancies that could be used to achieve the same false-positive rates. For example, at a 2% 
false-positive rate a risk cut-off of 1 in 150 could be used for singleton pregnancies, 1 in 500 for 




This article is protected by copyright. All rights reserved. 
Discussion 
Our results show that the assumption that the pattern of marker levels seen in affected and 
unaffected singleton pregnancies will be proportionately the same in twin pregnancies is not the 
case. The median PAPP-A value in dichorionic affected twin pregnancies was lower than in 
unaffected twin pregnancies (0.79 times lower, Table 2) but not as low as in affected singleton 
pregnancies compared with unaffected singleton pregnancies (0.50 at 12 weeks’ gestation).[8] Also, 
the median free β-hCG level in affected twin pregnancies (monochorionic and dichorionic twin 
pregnancies combined) was higher than in unaffected twin pregnancies (1.43 times higher, Table 2) 
but not as high as in affected singleton pregnancies compared with unaffected singleton pregnancies 
(2.19 at 12 weeks’ gestation).[8]  
 
In monochorionic twin pregnancies screening performance is similar to that in singleton 
pregnancies. In dichorionic pregnancies the discrimination of PAPP-A and free β-hCG between 
affected and unaffected pregnancies is lower than that in singleton pregnancies. This means that 
screening performance in dichorionic twin pregnancies using the Combined test is less than has been 
previously estimated [7], but still improved over using nuchal translucency and maternal age alone. 
All monochorionic twins are monozygotic (identical) so averaging NT values in monochorionic twins 
is valid, however, about 10% of dichorionic pregnancies are monozygous [10] and in these cases not 
averaging the NT measurements will introduce some error in relation to how NT is used in the 
screening algorithm. This, however has a negligible effect on screening performance; among such 
pregnancies the detection rate of NT alone with age is only one percentage point lower than that for 
dichorionic dizygous twin pregnancies at a 3% false-positive rate, with no change in the detection 
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Our results are in general consistent with those of Madsen et al.[11] The median PAPP-A levels in in 
monochorionic and dichorionic affected twin pregnancies reported by Madsen et al were, 
respectively, 0.49 (95% CI 0.32-0.75) and 0.66 (0.56-0.78) compared with monochorionic and 
dichorionic unaffected twin pregnancies; in our study they were 0.42 (0.33-0.62) and 0.79 (0.67-
0.93). With respect to free β-hCG the corresponding values reported by Madsen et al are 0.85 (0.53-
1.37) and 1.41 (1.18-1.69) (not statistically significantly different) and 1.32 combined compared with 
1.43 (1.23-1.61) for all affected twins in our paper.  
 
Table 4 shows that for a given risk cut-off screening performance differs significantly between 
monochorionic and dichorionic twin pregnancies. This is mainly due to Down syndrome pregnancies 
being 66% less common in monochorionic twin pregnancies than in singleton pregnancies, but 34% 
more common in dichorionic than in singleton pregnancies [6], which leads to a 4-fold difference in 
the background maternal age related risk between monochorionic and dichorionic twin pregnancies. 
 
As an ultrasound scan is performed at 11-13 weeks’ to measure crown-rump length and NT, the 
chorionicity status can also be determined, and if chorionicity status in twin pregnancies is known, 
consideration could be given to the use of different risk cut-off levels in monochorionic and 
dichorionic twin pregnancies from those in singleton pregnancies to achieve a similar screening 
performance (see Table 5).  
 
In summary, our results indicate that it is still appropriate to use PAPP-A and free β-hCG as well as 
nuchal translucency in screening twin pregnancies, but appropriate revisions are needed to update 
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Table 1: Median marker values (95% confidence intervals) in twin pregnancies expressed in singleton based median MoM values, together with median 
MoM values in affected twin pregnancies based on the proportionality assumption (square brackets) 
  Down syndrome pregnancies   Unaffected pregnancies 
Marker Monochorionic (n=12) Dichorionic (n=49) p 







All twins   
(n=7302) 
NT                   
Affected twin(s) 1.94 (1.22-2.16) 1.95 (1.62-2.36)* 0.654 1.95 (1.64-2.15) 
 
- - - - 
Unaffected 
twin(s) - 1.03 (0.96-1.08)** - - 
 
0.98 (0.97-0.99) 1.00 (1.00-1.01) <0.001 1.00 (0.99-1.00) 
Free β-hCG 2.63 (1.79-3.22) [3.76] 2.60 (2.23-3.30) [2.93] 0.870 2.62 (2.45-3.13) 
 
1.84 (1.78-1.90) 1.98 (1.94-2.01) <0.001 1.94 (1.91-1.97) 
PAPP-A 0.83 (0.65-1.27) [0.80] 1.88 (1.60-2.17) [1.33] <0.001 1.62 (1.47-2.03)   2.03 (1.95-2.08) 2.37 (2.33-2.40) <0.001 2.28 (2.26-2.32) 
 
1The affected twin was not identified in 6 dichorionic pregnancies 
2In one dichorionic pregnancy one twin was affected with Down syndrome and the other twin was affected with trisomy 13. The NT from the fetus with 
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Table 2: Distribution parameters for the Combined test markers in Down syndrome and unaffected twin pregnancies expressed in MoM values for 
unaffected twin pregnancies (MoMT) 
    Down syndrome twin pregnancies   Unaffected twin pregnancies     
  




(log10) SD (log10) 
 








NT1                     
Monochorionic 
 
1.95  (1.67-2.20) 0.2900 0.2400 
 





1.95  (1.67-2.20)  
1.00 (0.99-1.00) 




1.00 (0.99-1.00)    
1.00 (0.99-1.00) 








1.43 (1.23-1.61) 0.1553 0.2209 
 




          Monochorionic 
 
0.42 (0.33-0.62) -0.3768 0.2995 
 
1.00 (0.99-1.01) 0.00 0.2017  
0.312-1.00 
Dichorionic   0.79 (0.67-0.93) -0.1024 0.2036     0.50-3.00 
1No statistically significant difference between affected fetuses from monochorionic and dichorionic twin pregnancies so overall median and standard 
deviation taken (see Table 1) 
2No statistically significant difference between monochorionic and dichorionic twin pregnancies (see Table 1) 
3Truncation limit set at point of risk reversal 
The correlation between free β-hCG and PAPP-A log10 MoMT values in unaffected twin pregnancies was 0.1790; the correlation coefficient between paired 
log10 NT MoMT values in unaffected dichorinic twin pregnancies was 0.4585; all other correlation coefficients were not statistically significant and taken as 
zero 
There were no statistically significant change in free β -hCG or PAPP-A MoMT values with gestational age in affected twin pregnancies (p=0.545 and p=0.345 
respectively) Similarly there was no change in NT MoMT values in monochorionic or dichorionic affected twin pregnancies with gestational age (p=0.703 and 
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Table 3: Down syndrome screening performance of the Combined test, and nuchal translucency (NT) with maternal age in twin pregnancies compared with 
performance in singleton pregnancies (12 completed weeks); detection rate (DR) for specified false-positive rate (FPR) and FPR for specified DR. 
  DR (%) for FPR of:-   FPR (%) for DR of:- 
Screening test 1% 2% 3% 4% 5% 
 
70% 75% 80% 85% 90% 
Combined test                       
Singleton pregnancies 79 83 86 87 88 
 
0.2 0.5 1.2 2.7 6.6 
            Twin pregnancies 
           Monochorionic  81 85 87 89 90 
 
0.2 0.4 0.9 2.1 5.2 
Dichorionic  66 71 74 77 79 
 
1.7 3.2 5.9 10.5 18.9 
All* 69 74 77 79 81 
 
1.4 2.6 4.9 8.8 16.2 
            NT + age 
           Singleton pregnancies 69 73 76 77 79 
 
1.1 2.8 5.8 11.1 21.2 
            Twin pregnancies 
           Monochorionic  68 72 74 76 78 
 
1.4 3.4 6.7 12.9 22.4 
Dichorionic  63 67 70 72 74 
 
2.9 5.6 9.3 15.3 26.1 
All* 64 68 71 73 75   2.6 5.2 8.8 14.8 25.4 







This article is protected by copyright. All rights reserved. 
 
Table 4: Down syndrome screening performance of the Combined test, and nuchal translucency (NT) with maternal age in twin pregnancies compared with 
performance in singleton pregnancies (12 completed weeks); detection rate (DR) and false-positive rate (FPR) for specified term risk cut-offs. 
  Risk cut-off 
 
1 in 50 
 
1 in 75 
 
1 in 100 
 
1 in 150 
 
1 in 200 
 
1 in 400 
 




































Combined test                                         













                     Twin pregnancies 
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                     Twin pregnancies 


























All* 63 0.8   68 2.1   70 3.4   75 6.3   78 8.7   85 16.4   90 31.9 
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Table 5:  Screening policy options; risk cut-off (term) according to false-positive rate 




rate Monochorionic Dichorionic 
1% 1 in 80 1 in 250 1 in 40 
2% 1 in 150 1 in 500 1 in 60 
3% 1 in 250 1 in 750 1 in 80 
4% 1 in 300 1 in 1000 1 in 100 
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Figure 1: Median free β-hCG and PAPP-A multiple of the median values for unaffected singleton 
pregnancies in unaffected twin pregnancies according to chorionicity and gestational age together 
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*Monochorionic unaffected twin pregnancies; slope of the regression line for free β-hCG not 
statistically significantly different from zero; horizontal line shows the overall median MoM of 1.83.  
Dichorionic unaffected twin pregnancies; median free β-hCG MoM =100.07044+0.00254×gestational age (days).  
Monochorionic unaffected twin pregnancies; median PAPP-A MoM = 10-0.44274+0.00847×gestational age (days). 
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Figure 2: Median free β-hCG and PAPP-A multiple of the median values for unaffected twin 
pregnancies in affected twin pregnancies according to chorionicity and gestational age together with 
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Figure 3: Down syndrome detection rates for a 3% false-positive rate using nuchal translucency (NT) 
with maternal age or the Combined test (CT), which includes maternal age, in singleton (12 
completed weeks), monochorionic twin and dichorionic twin pregnancies 
 
 
